For Healthcare Professionals
Articles and Resources for ROS1+ Patients, Families, and Health Professionals.
Parenting after a ROS1+ Cancer Diagnosis
Thanks to ROS1ders’ Partner Turning Point Therapeutics
The Few…The Proud…The ROS1ders!
The ROS1ders Interview Dr. Ross Camidge
pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC
Donating ROS1 Tissue
ROS1 by the Numbers
ROS1 News From Europe
Addario to Merge with Lung Cancer Alliance
Entrectinib granted priority review for ROS1 NSCLC and NTRK solid tumors
Advocating for ROS1
Thinking about a “drug vacation” from crizotinib? Read this first!
Crizotinib approved for ROS1 in Australia
NCCN Guidelines recommend lorlatinib for second-line ROS1+ NSCLC
U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC
Presentations on ROS1+ Cancer at IASLC #WCLC2018
Detection of ROS1 rearrangement in lung cancer remains “complex”
Crizotinib may be effective again after chemo
TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TP
Pfizer new lung cancer drug is successful for funding.
The Unnecessary Cruelty of Clinical Trials
Patients’ Tips on How to Deal with Common Side Effects of Crizotinib (aka Xalkori)